Linked Life Data

15218339

Source:http://linkedlifedata.com/resource/pubmed/id/15218339

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15218339rdf:typepubmed:Citationlld:pubmed
pubmed-article:15218339lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C0253023lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C0021920lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C1539477lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C0086860lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:15218339lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:15218339pubmed:issue1lld:pubmed
pubmed-article:15218339pubmed:dateCreated2004-7-26lld:pubmed
pubmed-article:15218339pubmed:abstractTextWe studied the association between multiple sclerosis (MS) and a novel single nucleotide polymorphism (SNP), A/T(735)G/C, localized in intron IV of the ApoI/Fas gene, which is recognized by the restrictase MaeI. Fas-MaeI genotypes were screened in chromosomes of 215 healthy individuals and 312 relapsing MS patients of Spanish extraction. We also analyzed the interaction of this new intragenic marker with others previously associated with MS: class II HLA-DRB1*1501, Fas-MvaI and Fas ligand. The distribution of Fas-MaeI genotypes was in equilibrium in the control cohort, while a significant disequilibrium was observed in the patient group (chi(2) = 16; p = 0.0003). Fas-MaeI genotypes were statistically different in the MS and control groups, but the allele frequencies were not. Sharing of MvaI/MaeI genotypes of the promoter/intron IV region did not differ between patients and controls. We failed to find different frequencies of ApoI/Fas genotypes in the population of MS carriers of the class II HLA-DRB1*1501 allele. The case/control comparative study showed a relative risk (OR close to 1.6) of MS in individuals harboring the T and A alleles of Fas- MaeI and Fas ligand, respectively. In conclusion, our findings suggest a weak association between the intronic marker Fas-MaeI and MS and a relative interaction with Fas ligand in an MS cohort of South Spanish extraction.lld:pubmed
pubmed-article:15218339pubmed:languageenglld:pubmed
pubmed-article:15218339pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:citationSubsetIMlld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15218339pubmed:statusMEDLINElld:pubmed
pubmed-article:15218339pubmed:issn0014-3022lld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:LucasMiguelMlld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:ZayasMaría...lld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:SolanoFrancis...lld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:IzquierdoGuil...lld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:ChadliAmalAlld:pubmed
pubmed-article:15218339pubmed:authorpubmed-author:DincaLuminita...lld:pubmed
pubmed-article:15218339pubmed:copyrightInfoCopyright 2004 S. Karger AG, Basellld:pubmed
pubmed-article:15218339pubmed:issnTypePrintlld:pubmed
pubmed-article:15218339pubmed:volume52lld:pubmed
pubmed-article:15218339pubmed:ownerNLMlld:pubmed
pubmed-article:15218339pubmed:authorsCompleteYlld:pubmed
pubmed-article:15218339pubmed:pagination12-7lld:pubmed
pubmed-article:15218339pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:meshHeadingpubmed-meshheading:15218339...lld:pubmed
pubmed-article:15218339pubmed:year2004lld:pubmed
pubmed-article:15218339pubmed:articleTitleA study of promoter and intronic markers of ApoI/Fas gene and the interaction with Fas ligand in relapsing multiple sclerosis.lld:pubmed
pubmed-article:15218339pubmed:affiliationServicio de Biología Molecular, Hospital Universitario Virgen Macarena, Avda. Dr. Fedriani s/n, ES-41009 Seville, Spain. lucas@us.eslld:pubmed
pubmed-article:15218339pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15218339pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15218339pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:355entrezgene:pubmedpubmed-article:15218339lld:entrezgene
entrez-gene:356entrezgene:pubmedpubmed-article:15218339lld:entrezgene
entrez-gene:3123entrezgene:pubmedpubmed-article:15218339lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15218339lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15218339lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15218339lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15218339lld:pubmed